287 related articles for article (PubMed ID: 23175273)
81. Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals.
Aleo MD; Shah F; He K; Bonin PD; Rodrigues AD
Chem Res Toxicol; 2017 May; 30(5):1219-1229. PubMed ID: 28437613
[TBL] [Abstract][Full Text] [Related]
82. Effects of bile salt infusion on chlorpromazine-induced cholestasis in the isolated perfused rat liver.
Utili R; Tripodi MF; Abernathy CO; Zimmerman HJ; Gillespie J
Proc Soc Exp Biol Med; 1992 Jan; 199(1):49-53. PubMed ID: 1728036
[TBL] [Abstract][Full Text] [Related]
83. Rat precision-cut liver slices predict drug-induced cholestatic injury.
Starokozhko V; Greupink R; van de Broek P; Soliman N; Ghimire S; de Graaf IAM; Groothuis GMM
Arch Toxicol; 2017 Oct; 91(10):3403-3413. PubMed ID: 28391356
[TBL] [Abstract][Full Text] [Related]
84. In Vitro Drug-Induced Liver Injury Prediction: Criteria Optimization of Efflux Transporter IC50 and Physicochemical Properties.
Yucha RW; He K; Shi Q; Cai L; Nakashita Y; Xia CQ; Liao M
Toxicol Sci; 2017 Jun; 157(2):487-499. PubMed ID: 28369588
[TBL] [Abstract][Full Text] [Related]
85. Role of Hepatocyte Transporters in Drug-Induced Liver Injury (DILI)-In Vitro Testing.
Tátrai P; Erdő F; Krajcsi P
Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678658
[TBL] [Abstract][Full Text] [Related]
86. Mitogen-activated protein kinases are involved in hepatocanalicular dysfunction and cholestasis induced by oxidative stress.
Toledo FD; Basiglio CL; Barosso IR; Boaglio AC; Zucchetti AE; Sánchez Pozzi EJ; Roma MG
Arch Toxicol; 2017 Jun; 91(6):2391-2403. PubMed ID: 27913845
[TBL] [Abstract][Full Text] [Related]
87. Effect of bile acids on the expression of MRP3 and MRP4: An In vitro study in HepG2 cell line.
Pérez-Pineda SI; Baylón-Pacheco L; Espíritu-Gordillo P; Tsutsumi V; Rosales-Encina JL
Ann Hepatol; 2021; 24():100325. PubMed ID: 33582321
[TBL] [Abstract][Full Text] [Related]
88. Inhibition of canalicular and sinusoidal taurocholate efflux by cholestatic drugs in human hepatoma HepaRG cells.
Le Vée M; Moreau A; Jouan E; Denizot C; Parmentier Y; Fardel O
Biopharm Drug Dispos; 2022 Dec; 43(6):265-271. PubMed ID: 36195987
[TBL] [Abstract][Full Text] [Related]
89. A Change in Bile Flow: Looking Beyond Transporter Inhibition in the Development of Drug-induced Cholestasis.
Garzel B; Zhang L; Huang SM; Wang H
Curr Drug Metab; 2019; 20(8):621-632. PubMed ID: 31288715
[TBL] [Abstract][Full Text] [Related]
90. In silico identification and in vitro validation of potential cholestatic compounds through 3D ligand-based pharmacophore modeling of BSEP inhibitors.
Ritschel T; Hermans SM; Schreurs M; van den Heuvel JJ; Koenderink JB; Greupink R; Russel FG
Chem Res Toxicol; 2014 May; 27(5):873-81. PubMed ID: 24713091
[TBL] [Abstract][Full Text] [Related]
91. Uremic solutes modulate hepatic bile acid handling and induce mitochondrial toxicity.
Weigand KM; Schirris TJJ; Houweling M; van den Heuvel JJMW; Koenderink JB; Dankers ACA; Russel FGM; Greupink R
Toxicol In Vitro; 2019 Apr; 56():52-61. PubMed ID: 30639138
[TBL] [Abstract][Full Text] [Related]
92. Evidence that decreased expression of sinusoidal bile acid transporters accounts for the inhibition by rapamycin of bile flow recovery following liver ischemia.
Afroz F; Jonkman E; Hua J; Kist A; Zhou Y; Sokoya EM; Padbury R; Nieuwenhuijs V; Barritt G
Eur J Pharmacol; 2018 Nov; 838():91-106. PubMed ID: 30179613
[TBL] [Abstract][Full Text] [Related]
93. Cholangiocyte organoids to study drug-induced injury.
Wang Z; Xing C; van der Laan LJW; Verstegen MMA; Spee B; Masereeuw R
Stem Cell Res Ther; 2024 Mar; 15(1):78. PubMed ID: 38475870
[TBL] [Abstract][Full Text] [Related]
94. A Dynamic Mathematical Model of Bile Acid Clearance in HepaRG Cells.
Kaschek D; Sharanek A; Guillouzo A; Timmer J; Weaver RJ
Toxicol Sci; 2018 Jan; 161(1):48-57. PubMed ID: 29029322
[TBL] [Abstract][Full Text] [Related]
95. From the Cover: MechanisticInsights in Cytotoxic and Cholestatic Potential of the Endothelial Receptor Antagonists Using HepaRG Cells.
Burbank MG; Sharanek A; Burban A; Mialanne H; Aerts H; Guguen-Guillouzo C; Weaver RJ; Guillouzo A
Toxicol Sci; 2017 Jun; 157(2):451-464. PubMed ID: 28369585
[TBL] [Abstract][Full Text] [Related]
96. Functional human induced hepatocytes (hiHeps) with bile acid synthesis and transport capacities: A novel in vitro cholestatic model.
Ni X; Gao Y; Wu Z; Ma L; Chen C; Wang L; Lin Y; Hui L; Pan G
Sci Rep; 2016 Dec; 6():38694. PubMed ID: 27934920
[TBL] [Abstract][Full Text] [Related]
97. Liver metabolic/oxidative stress induces hepatic and extrahepatic changes in the expression of the vitamin C transporters SVCT1 and SVCT2.
Hierro C; Monte MJ; Lozano E; Gonzalez-Sanchez E; Marin JJ; Macias RI
Eur J Nutr; 2014; 53(2):401-12. PubMed ID: 23708151
[TBL] [Abstract][Full Text] [Related]
98. Tsumura-Suzuki obese diabetic mice-derived hepatic tumors closely resemble human hepatocellular carcinomas in metabolism-related genes expression and bile acid accumulation.
Takahashi T; Deuschle U; Taira S; Nishida T; Fujimoto M; Hijikata T; Tsuneyama K
Hepatol Int; 2018 May; 12(3):254-261. PubMed ID: 29651702
[TBL] [Abstract][Full Text] [Related]
99. Lactation during cholestasis: Role of ABC proteins in bile acid traffic across the mammary gland.
Blazquez AMG; Macias RIR; Cives-Losada C; de la Iglesia A; Marin JJG; Monte MJ
Sci Rep; 2017 Aug; 7(1):7475. PubMed ID: 28785115
[TBL] [Abstract][Full Text] [Related]
100. Assessing the Risk of Drug-Induced Cholestasis Using Unbound Intrahepatic Concentrations.
Riede J; Poller B; Huwyler J; Camenisch G
Drug Metab Dispos; 2017 May; 45(5):523-531. PubMed ID: 28254950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
